AVPR2 and autosomal dominant polycystic kidney disease: Current ADPKD drugs include tolvaptan (a vasopressin V2 receptor antagonist and the only FDA-approved drug for ADPKD) and the investigative drug metformin, which has been reported to inhibit cystogenesis by activating the AMP-activated protein kinase (AMPK) pathway.4,5